1.	A Korean Study of Efficacy and Safety of Aprepitant-based Triple Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in the First Cycle of Moderately Emetogenic Chemotherapy (Non-doxorubicin Hydrochloride [Adriamycin] and Cyclophosphamide Regimens) (MK-0869-225 AM1) (KMEC) Phase: Phase IV Type: Supportive care Status: Approved-not yet active Age: 21 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 0869-225, MK-0869-225, NCT01636947
2.	Ondansetron Versus Aprepitant Plus Ondansetron for Emesis Phase: Phase II Type: Supportive care, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 2008-0615, NCT00954941
3.	Study of Aprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting (CINV) in Colorectal Cancer Patients - SENRI Trial Phase: No phase specified Type: Supportive care, Treatment Status: Active Age: 20 and over Sponsor: Other Protocol IDs: SENRI, NCT01344304
4.	Developing Individualized Strategies to Prevent Nausea and Vomiting Phase: No phase specified Type: Biomarker/Laboratory analysis, Supportive care Status: Approved-not yet active Age: 21 to 70 Sponsor: NCI, Other Protocol IDs: 1R01CA163074-01A1, 10831533, NCT01393288